Introduction
============

Asthma has a high prevalence of 5--10% ([@r13]), and in 2010 ranked as the 28th leading cause of disability-adjusted life years worldwide ([@r30]). Asthma is a heterogeneous disease that may appear at any age (most often in childhood), and can persist, possibly remit, or show variable activity over time ([@r40]; [@r46]). The complexity of this chronic disease is particularly challenging, and more research is needed on the environmental determinants of the disease (and not only on the acute triggers of attacks), because the increase in asthma incidence over the last decades ([@r13]) strongly suggests a role of environmental factors. The role of air pollutants in triggering asthma exacerbations in young and adult asthma patients is established ([@r32]; [@r42]). Several studies support the role of air pollution in the development of asthma in childhood ([@r2]; [@r26]), but not all ([@r29]). The role of air pollution in adult-onset asthma (i.e., asthma incidence) has been investigated in only a few studies ([@r2]; [@r20]; [@r47]) and should not be extrapolated from studies in children because childhood-onset and adult-onset asthma are two distinct asthma phenotypes that have, at least partly, different clinical, biological, and genetic characteristics ([@r46]). Among studies in adults, only four have used individually assigned air pollution estimates at home addresses. A small Swedish case--control study (203 cases and 203 controls) suggested an association of traffic-related nitrogen dioxide (NO~2~) with asthma incidence, but the study lacked statistical power ([@r27]). Both the Respiratory Health in Northern Europe (RHINE) study (3,824 participants) ([@r28]) and the European Community Respiratory Health Survey (ECRHS) (4,185 participants) ([@r22]) reported a positive association between NO~2~ and asthma incidence. The Swiss Study on Air Pollution and Health in Adults (SAPALDIA) found similar results, but only in never-smokers and using source-specific models of local traffic-related particulate matter (PM) as a marker of exposure ([@r25]). A recent U.S. study suggested an association of PM~2.5~ (≤ 2.5 μm) with incident asthma in women ([@r47]). Two recent reviews concluded that the existing evidence suggests a possible role of air pollution in adult-onset asthma but that the evidence is not conclusive because the studies lacked of power, suggesting the need for larger cohorts ([@r2]; [@r20]).

The European Study of Cohorts for Air Pollution Effects (ESCAPE) developed, for the first time at large scale, fully standardized air pollution measurement, modeling, and assignment methods to individually characterize home outdoor exposure ([@r5]; [@r14]). We took advantage of a follow-up of \> 10 years among 23,704 adults in six prospective cohorts from eight countries to assess the association between long-term exposure to ambient air pollution and asthma incidence in adulthood.

Methods
=======

*Study population and assessment of asthma incidence*. Six prospective cohorts from 24 areas in eight countries contributed to the analysis of asthma incidence in adulthood over a 10-year period. Three of these cohorts \[ECRHS ([@r12]), the French Epidemiological study on the Genetics and Environment of Asthma (EGEA) ([@r38]), and SAPALDIA ([@r1])\] were respiratory epidemiological cohorts, with detailed information regarding respiratory symptoms, bronchial challenge tests, and sensitization. The three others were general health cohorts. The study on the influence of Air pollution on Lung function, Inflammation and Aging (SALIA; [@r37]) and SAPALDIA were originally designed to investigate effects of air pollution. ECRHS, SAPALDIA, and the Medical Research Council's National Survey of Health and Development (NSHD) ([@r24]) corresponded to a representative sample of subjects of predefined areas. The Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale (E3N) ([@r11]) and SALIA were conducted in elderly women. EGEA included by design a high proportion of relatives of asthma patients recruited in chest clinics. ECRHS, EGEA, and SAPALDIA were initiated in the 1990s and followed-up 9--12 years later. NSHD is a birth cohort of participants born in 1946 and with \> 20 regular follow-ups since then; for this analysis, baseline was considered in 1989 and follow-up in 1999. E3N women were recruited in 1990 and followed-up every 2 years; the last follow-up included for this analysis is the one from 2008. SALIA women were recruited in 1985; a questionnaire follow-up was conducted in 2006 and a second from 2007 to 2010. For detailed information on each study, see Supplemental Material, Table S1 and Figure S1.

For each cohort, the absence of asthma at baseline and the incidence of asthma during follow-up were defined as shown in Supplemental Material, Table S2, according to the availability of each cohort's variables. Two principles were followed regarding the assessment of asthma: harmonization across cohorts and optimal use of available information. Depending on the cohort, asthma was defined by two standardized questionnaires: the British Medical Research Council questionnaire ([@r35]), which originated in the 1960s, and the ECRHS questionnaire ([@r9]), designed in the 1990s. For all studies, asthma incidence was defined only in subjects without asthma at baseline. To further improve the specificity of our asthma incidence definition ([@r33]; [@r41]), we also excluded from the population at risk of new-onset asthma any participant who reported at baseline three of five asthma-like symptoms in the preceding 12 months (wheeze and breathlessness; chest tightness; attack of shortness of breath at rest; attack of shortness of breath after exercise; awakening by attack of shortness of breath); this information was available in three of the six cohorts (ECRHS, EGEA, SAPALDIA) ([@r7]). (For flow charts and criteria used to classify asthma for each cohort, see Supplemental Material, Table S2 and Figure S1.) In ECRHS, SAPALDIA, and EGEA, objective asthma-related traits were available. Methacholine bronchial provocation tests were performed and bronchial responsiveness defined when the provocative dose to decrease by 20% the forced expiratory flow volume in 1 sec was ≤ 1 mg cumulative dose of methacholine. Allergic sensitization was assessed as at least one skin prick test or at least one specific immunoglobulin E \> 0.35 U/mL (see [Table 1](#t1){ref-type="table"} for details). In all studies, hay fever was recorded by questionnaire at baseline and follow-up. Eczema was assessed in some studies. Moving status was defined based on the available data, considering addresses (geocodes) when baseline address was available and reported move assessed through questionnaire otherwise. Ethical approval was obtained for each cohort/center from the appropriate institutional or regional ethics committee, and written consent was obtained from each participant.

###### 

Characteristics of participants with NO~2~ exposure estimates in the ESCAPE analyses, by study (*n*) and outcome.

  Characteristic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    All (23,704)   ECRHS (3,802)   EGEA (517)^*a*^   E3N (12,763)   NSHD (2,339)   SALIA (2,073)   SAPALDIA (2,210)                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------- ----------------- -------------- -------------- --------------- ------------------ ---------- -------- ---------- -------- ---------- --------- -----------
  *n*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               22,447         1,257           3,657             145            468            49              12,012             751        2,245    94         1,925    148        2,140     70
  Female (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        82             89              52                67\*           54             57              100                100        52       60         100      100        53        61
  Age at baseline (years) (mean ± SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               42             46              34 ± 7            34 ± 7         41 ± 12        36 ± 13\*       49 ± 7             49 ± 6\*   43 ± 0   43 ± 0     54 ± 1   55 ± 1     42 ± 12   38 ± 11\*
  Age ≥ 50 at baseline (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          35             36              0                 0              23             14\*            43                 38\*       0        0          100      100        31        16\*
  Age at follow-up (years) (mean ± SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              60             60              43 ± 7            42 ± 7         52 ± 12        47 ± 13\*       65 ± 7             64 ± 6     53 ± 0   53 ± 0     71 ± 3   72 ± 3\*   53 ± 12   49 ± 11
  BMI at baseline (kg/m^2^) (mean ± SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             23             24              24 ± 4            24 ± 5         23 ± 3         23 ± 5          22 ± 3             23 ± 3\*   25 ± 4   27 ± 5\*   27 ± 4   27 ± 4     24 ± 4    24 ± 4
  BMI ≥ 25 at baseline (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          26             30              33                35             26             31              13                 18\*       45       67\*       67       66         31        29
  Smoking status at baseline (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Current smoker                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    22             22              36                30             25             47\*            17                 19         26       29         11       16         36        24
  Ever-smoker                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       29             29              21                26             24             10\*            34                 34         42       39         9        5          21        27
  Never-smoker                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      49             49              43                45             51             43\*            50                 46         31       32         80       79         43        49
  Maximum education at baseline or follow-up (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Low level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         12             13              23                28             26             17              2                  3\*        41       51         22       25         7         9
  Medium level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      24             21              34                28             22             15              6                  8\*        48       42         49       51         62        60
  High level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        64             66              43                45             52             67              91                 88\*       11       8          29       24         30        31
  Movers (between baseline and follow-up) (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       33             33              45                42             45             55              27                 31         39       37         18       15         48        50
  Asthma-related variables                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Methacholine test,^*b*^ baseline (*n*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            4,837          197             2,871             112            385            38              NA                 NA         NA       NA         NA       NA         1,581     47
  PD20 ≤ 1 mg (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   9              28              8                 38\*           12             29\*            NA                 NA         NA       NA         NA       NA         9         6
  Methacholine test,^*b*^ follow-up (*n*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           3,499          147             2,197             94             264            25              NA                 NA         NA       NA         NA       NA         1,038     28
  PD20 ≤ 1mg (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    9              40              10                44\*           12             48\*            NA                 NA         NA       NA         NA       NA         5         18\*
  SPT/spIgE,^*c*^ baseline (*n*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    5,207          228             2,937             119            457            49              NA                 NA         NA       NA         NA       NA         1,813     60
  Allergic sensitization (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        27             50              25                52\*           35             45              NA                 NA         NA       NA         NA       NA         28        50\*
  SPT/spIgE,^*c*^ follow-up (*n*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   4,684          194             2,859             112            371            40              NA                 NA         NA       NA         NA       NA         1,454     42
  Allergic sensitization (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        27             55              24                55\*           33             55\*            NA                 NA         NA       NA         NA       NA         30        55\*
  Hay fever at baseline (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         13             26              19                46\*           25             35              11                 25\*       16       19         5        10\*       17        40\*
  Hay fever at follow-up (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        11             27              21                54\*           29             64\*            5                  17\*       23       40\*       5        19\*       18        51\*
  Eczema at baseline (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            34             43              33                43\*           23             29              NA                 NA         NA       NA         NA       NA         38        51\*
  Eczema at follow-up (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           27             36              35                48\*           25             37              NA                 NA         NA       NA         4        13\*       35        57\*
  Abbreviations: BMI, body mass index; NA, not available; PD20, dose of methacholine required to produce a 20% fall in the forced expiratory volume in 1 sec; SPT/splgE, skin prick test/specific immunoglobulin E. Percentages are column percentages. ^***a***^In EGEA, the 517 participants belong to 372 families, and 24% of the participants had at least one parent with asthma. ^***b***^Bronchial hyperresponsiveness was defined dichotomously as PD20 ≤ 1 mg \[the common dose used in all three studies (ECRHS, EGEA, and SAPALDIA)\]. ^***c***^Allergic sensitization at baseline and follow-up for ECRHS, EGEA, and SAPALDIA was defined as at least one skin prick test (SPT) positive or at least one specific immunoglobulin E \> 0.35 U/mL. In ECRHS, allergic sensitization was defined at baseline as any positive SPT (7 allergens tested) and allergic sensitization at follow-up was defined as any specific IgE concentration \> 0.35 U/mL (4 IgEs tested). In EGEA and SAPALDIA, allergic sensitization at baseline or follow-up was defined as any positive SPT (EGEA: 11 and 12 allergens tested at baseline and follow-up, respectively; SAPALDIA: 8 allergens tested). \**p* \< 0.05 comparing cohort participants with and without incident asthma.                                                                                                                                                                                  

The covariates were chosen based on evidence from previous studies ([@r22]; [@r25]; [@r28]) but also taking into account the assessment and quality of available data within the ESCAPE cohorts. Smoking (current, former, never), maximum educational level (low, medium, high), and overweight \[body mass index (BMI) \< 25, ≥ 25 kg/m^2^, except in ECRHS where an additional missing category was created because \> 20% of data were missing for this variable\] were considered in the analysis.

City/area refers to the city in ECRHS, EGEA, E3N, and SAPALDIA and the country in NSHD (England, Wales, and Scotland). All SALIA participants came from one area.

*Exposure data*. Measurements of NO~2~/NO~x~ (nitrogen oxides) were conducted in three seasons in 2010 or 2011 using passive samplers in the 24 areas. Areas refers to cities (with or without their metropolitan areas) in most of the cases, except in the United Kingdom where it is the whole country and in the Ruhr region in Germany where it is an urban area including several cities. PM monitoring campaigns were conducted in 12 areas. Exposure estimates at the participants' addresses at follow-up \[NO~2~, NO~x~, PM~10~ (≤ 10 μm), PM~2.5~, PM~2.5absorbance~, PM~coarse~\] derived from land use regression (LUR) models were used as primary exposure covariates ([@r6]; [@r14]; see also <http://www.escapeproject.eu>). Back-extrapolated exposure estimates for NO~2~ and PM~10~ were used for sensitivity analyses because ESCAPE air pollution measurement campaigns took place after the health surveys for most cohorts. The back-extrapolated concentration was estimated by multiplying the modeled ESCAPE annual mean concentration by the ratio between average annual concentrations as derived from the routine monitoring site(s) for the period in the past and for the ESCAPE measurement period time ([@r6]). Exposures were back-extrapolated to the follow-up period using routinely available air pollution monitoring data, but could not be extrapolated to baseline for all the areas because of a lack of earlier monitoring data for some cities, particularly for PM~10~. Furthermore, baseline addresses were not available in all the cohorts. Traffic exposure indicators, traffic intensity (on the nearest road), and traffic load (in a 100-m buffer) were derived from geographic databases.

*Data analysis*. The following cohort-specific random-effects logistic regressions were performed for all air pollution metrics: unadjusted (model 1), adjusted for age and sex (model 2), and additionally adjusted for smoking, overweight, and education level at baseline (model 3, the main model). Cox regression analysis was not used due to imprecision of the date of onset. The heterogeneity of the effect estimates between the cohorts was tested using the chi-square test. Meta-analytic estimates were estimated using fixed-effects models in the absence of heterogeneity between cohorts (*p*-value of heterogeneity \> 0.1), and using random-effects models when heterogeneity between cohorts was present. The *I*^2^ statistic was calculated for quantifying heterogeneity. For meta-analyses of subgroups (age, sex, and smoking status), meta-analytic stratum-specific estimates were derived and were compared between strata. Cohort-specific estimates in subgroup analyses were conducted using model 3, but without taking into account random effects per city/area because random-effects models encountered convergence problems.

Because NO~2~ is not measured near busy roads, models of associations with traffic variables were adjusted for background NO~2~. Random effects were used for the main relevant cluster for each cohort (city/area for E3N, ECRHS, NSHD, and SAPALDIA, or family for EGEA).

Sensitivity analyses were conducted *a*) to address the robustness of the association to a change in the window of exposure (by using back-extrapolated NO~2~ and PM~10~); *b*) to address the possible impact of the exposure models' performance \[by restricting analyses to areas where exposure models had the highest predictive value (cross-validation *R*^2^ \> 0.6)\]; *c*) to better compare the NO~2~ with the PM results (by restricting NO~2~ analyses to participants who also had PM measurements); *d*) to unmask a possible effect of one pollutant over the other using a two-pollutant model (NO~2~ and PM~10~); *e*) excluding individuals with a self-reported age-at-onset ≥ 2 years prior baseline according to record at follow-up, to better capture adult-onset asthma and not reappearance of childhood onset of asthma ([@r22]); this analysis is referred to as incidence with coherent age of onset in tables; *f*) excluding individuals with exposures at both upper and lower 5% extremes of pollutant values; and *g*) adjusting for "study city/area" as a fixed effect instead of random effect, as used before ([@r22]) but debated ([@r31]). Stratified analyses were conducted by age (\< 50 or ≥ 50 years), sex, and smoking (ever- or never-smokers) and analyses restricted to nonmovers were conducted. We investigated the robustness of the meta-analyses estimates by excluding consecutively each cohort. We performed further analyses within the ECRHS cohort to allow direct comparison with a previous ECRHS publication ([@r22]) that estimated NO~2~ using the APMoSPHERE (Air Pollution Modelling for Support to Policy on Health and Environmental Risk in Europe) model, a 1 × 1 km surface model developed using GIS-based techniques ([@r43]).

All the results are shown for an increase of 10 μg/m^3^ of NO~2~ and PM~10~, 5 μg/m^3^ of PM~2.5~ and PM~coarse~, 10^--5^/m^1^ of PM~2.5absorbance~ and 20 μg/m^3^ of NO~x~. For traffic measures, the results are shown for an increase of 5,000 vehicles/day for traffic intensity on the nearest road and four millions vehicles × m/day for traffic load in major roads within a 100-m buffer. Analyses used Stata version 12 (StataCorp, College Station, TX, USA).

Results
=======

*Population*. The six cohorts contributed to 1,257 incident cases of asthma for the total population of 23,704 participants ([Table 1](#t1){ref-type="table"}). Cohorts differed by several characteristics, reflecting recruitment differences. Asthma incidence rates varied from 2.9/1,000/year in SAPALDIA to 8.3/1,000/year in EGEA. In the three cohorts (ECRHS, EGEA, SAPALDIA) with available data, participants who developed asthma after baseline (i.e., incident asthma cases) were more likely than other participants to be classified as having bronchial hyperresponsiveness (BHR) at baseline (28% vs. 9% with a positive methacholine test), and were even more likely to have BHR at follow-up (40% compared with 9%). Compared with subjects who did not develop asthma, those with incident asthma exhibited more allergic sensitization, before (baseline) and after (follow-up) the onset of asthma. Hay fever was twice as common among participants with incident asthma compared with those without asthma (except for NSHD and EGEA at baseline).

*Air pollution and traffic metrics*. Mean and median air pollution exposures were lower for the NSHD cohort compared with the other five cohorts, though distributions overlapped among the cohorts ([Figure 1](#f1){ref-type="fig"}; see also Supplemental Material, Table S3). The highest mean NO~2~ concentration was found in E3N (31 ± 13 μg/m^3^) and the lowest in NSHD (22 ± 7 μg/m^3^). For PM~10~, the highest mean concentration was found in SALIA (27 ± 2 μg/m^3^) and the lowest in NSHD (16 ± 2 μg/m^3^). Cohort-specific interquartile ranges (IQRs) indicated substantial variability in the exposure contrasts within cohorts, ranging from 8 to 20 μg/m^3^ and 2 to 8 μg/m^3^ for NO~2~ and PM~10~, respectively (see Supplemental Material, Table S3). The highest correlation coefficients were always seen between NO~2~ and NO~x~ (*r* \> 0.90) (see Supplemental Material, Table S4). Correlation coefficients between NO~2~ and PM~10~ varied from 0.53 in E3N to 0.83 in SAPALDIA. Correlation coefficients between the different air pollutant concentrations and the traffic indicators showed wide between-cohort heterogeneity (from 0.06 for NO~2~ and traffic intensity in NSHD to 0.81 for PM~2.5absorbance~ and traffic load within a 100-m buffer in EGEA) (Table S4). All the LUR models had a leave-one-out cross validation *R*^2^ \> 50%, and most of them \> 80% ([@r5]; [@r14]) (see Supplemental Material, Table S5).

![NO~2~ and PM~10~ concentrations (μg/m^3^) by study. Boxes extend from the 25th to the 75th percentile, bars inside the boxes represent the median, and whiskers indicate the minimum and maximum values.](ehp.1408206.g001){#f1}

*Associations between air pollutants and traffic metrics and asthma incidence*. The unadjusted, simple (adjusted by sex and age), and fully adjusted models provided similar results in individual cohorts ([Table 2](#t2){ref-type="table"}). The fully adjusted meta-analytic estimate for NO~2~ was positive \[odds ratio (OR) = 1.10; 95% confidence interval (CI): 0.99, 1.21; *p* = 0.10\]. The association did not change when using the back-extrapolated NO~2~ ESCAPE estimates (OR = 1.10; 95% CI: 1.00, 1.20) ([Table 2](#t2){ref-type="table"} and [Figure 2](#f2){ref-type="fig"}). When adjusting by city/area as a fixed effect (instead of random effect), the OR for NO~2~ increased to 1.14 (95% CI: 1.01, 1.29) ([Table 3](#t3){ref-type="table"}), changes being driven mainly by an increased association estimate in ECRHS (OR = 1.41; 95% CI: 1.10, 1.80 instead of OR = 1.07; 95% CI: 0.92, 1.23).

###### 

Meta-analyses of associations between air pollutants and traffic indicators and the risk for asthma incidence.

  Exposure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Increase                     OR (95% CI)        Heterogeneity between cohorts (model 3)                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------ ----------------------------------------- ------------------ ------ ------
  NO~x~, no. of participants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   23,693             23,693                                    22,814                    
  NO~2~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           10 μg/m^3^                   1.11 (1.00,1.23)   1.04 (0.99,1.09)                          1.10 (0.99,1.21)   46.2   0.10
  NO~2~ back-extrapolated to follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            10 μg/m^3^                   1.10 (1.00,1.21)   1.04 (0.99,1.09)                          1.10 (1.00,1.20)   49.6   0.08
  NO~x~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           20 μg/m^3^                   1.09 (1.00,1.18)   1.04 (0.99,1.08)                          1.04 (0.99,1.08)   39.8   0.14
  PM, no. of participants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      17,798^*b*^        17,798^*b*^                               17,098^*b*^               
  PM~10~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          10 μg/m^3^                   1.05 (0.89,1.24)   1.05 (0.89,1.24)                          1.04 (0.88,1.23)   0.0    0.44
  PM~10~ back-extrapolated to follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           10 μg/m^3^                   1.04 (0.88,1.24)   1.04 (0.88,1.24)                          1.04 (0.87,1.24)   0.0    0.78
  PM~coarse~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      5 μg/m^3^                    0.98 (0.86,1.12)   0.98 (0.86,1.12)                          0.99 (0.87,1.14)   0.0    0.61
  PM~2.5~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         5 μg/m^3^                    1.11 (0.80,1.54)   1.04 (0.88,1.23)                          1.04 (0.88,1.23)   24.2   0.25
  PM~2.5absorbance~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               10^--5^/m                    1.05 (0.94,1.16)   1.05 (0.94,1.17)                          1.06 (0.95,1.19)   44.5   0.11
  Traffic variables, no. of participants^*a*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  22,430             22,428                                    21,551                    
  Traffic intensity on nearest road                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               5,000 vehicles/day           1.06 (0.98,1.14)   1.05 (0.98,1.13)                          1.05 (0.98,1.13)   56.4   0.04
  Traffic load in a 100-m buffer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4,000,000 vehicles × m/day   1.11 (0.94,1.31)   1.09 (0.94,1.27)                          1.10 (0.93,1.30)   57.4   0.04
  Model 1: unadjusted; model 2: adjusted for age and sex; model 3: adjusted for age, sex, smoking, overweight, and education level. The logistic regression models were conducted with random effects per city/area for each study except for SALIA, where there was only one area, and EGEA, where family structure was taken into account. The OR corresponds to the fixed effect when the *p*-value for heterogeneity was \> 0.1; when the *p*-value for heterogeneity was \< 0.1, the random effect is stated. *I*^2^: variation of estimate effect attributable to heterogeneity. ^***a***^For traffic intensity on the nearest road. ^***b***^For PM~10~.                                                                                                                       

![Associations of NO~2~ and NO~2~ back-extrapolated (per 10 μg/m^3^) on asthma incidence. Meta-analysis from the study-specific adjusted random-effects logistic regression models. The logistic regression models were adjusted for age, sex, smoking, overweight, and education level (model 3) with random effects per city/area for each study except for SALIA, where there is only one area, and EGEA, where family structure was taken into account. I-V: inverse variance weighted (fixed effect) pooled estimate of all studies. *I*^2^: variation in estimate effect attributable to heterogeneity. D+L: DerSimonian and Laird (random effect) pooled estimate of all studies. Study-specific odds ratios are shown as solid black diamonds with horizontal lines representing 95% CIs. The size of the blue squares reflects the statistical weight of the study in the meta-analyses. The meta-analytic odds ratios are shown as open black diamonds, the middle of the diamond corresponds to the odds ratio value, and the width of the diamond represents the 95% CI.](ehp.1408206.g002){#f2}

###### 

Results from random-effects meta-analyses for adjusted association between asthma incidence per 10-μg/m^3^ increase for NO~2~ and PM~10~: sensitivity and stratified analyses.

  Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No. of subjects   OR (95% CI) from model 3^*a*^   Heterogeneity between cohorts                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ------------------------------- ------------------------------- ------------------ ------- ------ ------- ------
  Main analyses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          22,814            17,098                          1.10 (0.99,1.21)                1.04 (0.88,1.23)   46.20   0.10   0.00    0.44
  Stratified analyses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  By age\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Restricted to age \< 50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                14,875            10,499                          1.08 (0.96,1.21)                1.07 (0.86,1.32)   56.60   0.06   10.60   0.35
  Restricted to age ≥ 50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 7,909             6,287                           1.02 (0.94,1.12)                1.05 (0.78,1.42)   0.00    0.54   0.00    0.72
  By sex\*\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Men only                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               4,098             2,264                           1.06 (0.92,1.24)                1.00 (0.63,1.59)   0.00    0.45   0.00    0.61
  Women only                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             18,725            14,751                          1.07 (0.97,1.19)                1.07 (0.91,1.26)   0.45    0.11   0.00    0.51
  By smoking status^\#^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Ever-smokers only                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      11,664^*b*^       8,576                           1.13 (0.99,1.29)                1.17 (0.79,1.74)   49.80   0.08   40.30   0.14
  Never-smokers only                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     11,159^*b*^       8,433                           1.01 (0.88,1.16)                1.10 (0.87,1.39)   50.00   0.08   0.00    0.52
  Sensitivity analyses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Using asthma incidence definition with coherent age of onset (NSHD excluded)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           19,935            14,585                          1.09 (0.93,1.28)                1.07 (0.59,1.93)   65.40   0.02   64.10   0.03
  Among nonmovers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        15,289            11,780                          1.04 (0.98,1.11)                1.12 (0.91,1.37)   0.00    0.50   0.00    0.88
  Excluding E3N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          10,715            7,185                           1.15 (1.03,1.27)                1.17 (0.82,1.66)   11.90   0.34   8.30    0.36
  Excluding ECRHS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        19,014            15,151                          1.12 (0.98,1.29)                1.13 (0.83,1.55)   56.50   0.06   15.40   0.32
  Excluding EGEA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         22,317            16,790                          1.03 (0.98,1.09)                1.02 (0.86,1.20)   3.50    0.39   0.00    0.79
  Excluding NSHD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         20,624            15,121                          1.08 (0.98,1.20)                1.06 (0.84,1.32)   49.10   0.10   13.80   0.33
  Excluding SALIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        20,768            15,052                          1.09 (0.98,1.21)                1.03 (0.85,1.26)   50.10   0.09   5.90    0.37
  Excluding SAPALDIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     20,632            16,191                          1.11 (1.00,1.24)                1.05 (0.89,1.24)   55.20   0.06   0.00    0.42
  Excluding 5% upper and lower extreme values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            20,642            15,412                          1.03 (0.97,1.10)                1.11 (0.89,1.37)   0.00    0.92   0.00    0.84
  Fixed effects between cities/areas within the same study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               22,814            17,098                          1.14 (1.01,1.29)                1.05 (0.86,1.29)   59.20   0.03   2.00    0.40
  Restricted to cities/areas with both NO~2~ and PM~10~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  17,097^*c*^       17,097^*c*^                     1.11 (0.99,1.24)                1.04 (0.88,1.23)   39.40   0.14   0.00    0.44
  Restricted to cities/areas with high goodness of fit for NO~2~ exposure models (*R*^2^ ≥ 0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          21,048            NA                              1.09 (0.98,1.21)                NA                 47.40   0.09   NA      NA
  Two-pollutant model (NO~2~, PM~10~)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    17,097            17,097                          1.17 (0.99,1.38)                0.98 (0.79,1.21)   46.20   0.10   0.00    0.42
  NA, not applicable. ^***a***^Meta-analysis from the study-specific adjusted logistic regression models. The logistic regression models were adjusted for age (except for the model stratified by age), sex (except for the model stratified by sex), smoking (except for the model stratified by smoking), overweight, and education level (model 3). Random effects are given per city/area (except for the model considering city/area as fixed effect) for each study except for SALIA, where there is only one area, and EGEA, where family structure was taken into account. ^***b***^Inconsistent *n* due to NSHD: 11,664 + 11,159 = 22,823 ≠ 22,814. ^***c***^Inconsistent *n* due to ECRHS. \**p*-Value for interaction between participants \< 50 and ≥ 50 years old for NO~2~: 0.88 and for PM~10~: 0.99. \*\**p*-Value for interaction between males and females for NO~2~: 0.66 and for PM~10~: 0.80. ^\#^*p*-Value for interaction between smokers and nonsmokers for NO~2~: 0.35 and for PM~10~: 0.69.                                                                                                                               

NO~2~ estimates were positive in all sensitivity and stratified analyses ([Table 3](#t3){ref-type="table"}). Using the stricter definition of asthma incidence with coherent age of onset did not modify the associations but confidence intervals were wider as power was decreased ([Table 3](#t3){ref-type="table"}). The analyses that were restricted to nonmovers or that excluded the 5% extreme value of the pollutants tended to decrease the associations (OR = 1.04; 95% CI: 0.98, 1.10 and OR = 1.03; 95% CI: 0.97, 1.10; respectively) ([Table 3](#t3){ref-type="table"}). Although cohort-specific association estimates suggested the possibility of between-cohort differences, with stronger estimates in the French EGEA cohort compared with the others ([Figure 2](#f2){ref-type="fig"}), heterogeneity among the cohorts was not statistically significant ([Table 2](#t2){ref-type="table"}). After consecutive exclusion of each cohort in the meta-analyses, the point estimate of the OR always remained positive, varying from 1.03 to 1.15, reaching significance for NO~2~ after the exclusion of E3N (OR = 1.15; 95% CI: 1.03, 1.27 with a decreased heterogeneity between cohorts' estimates) ([Table 3](#t3){ref-type="table"}) or SAPALDIA (OR = 1.11; 95% CI: 1.00, 1.24). A trend for stronger association between NO~2~ and asthma incidence was observed in ever-smokers compared with never-smokers (OR = 1.13; 95% CI: 0.99, 1.29 and OR = 1.01; 95% CI: 0.88, 1.16, respectively) (*p*-interaction = 0.35) ([Table 3](#t3){ref-type="table"}). Neither age nor sex modified the associations between NO~2~ and asthma incidence (*p*-interaction = 0.88 and 0.66, respectively) ([Table 3](#t3){ref-type="table"}). Restricting the analyses either to centers with both NO~2~ and PM~10~ measurements or to areas with a high goodness of fit of the LUR models did not modify the associations between NO~2~ and asthma incidence.

For PM~10~, meta-estimates were similar and not significant in models with or without back-extrapolation (OR = 1.04; 95% CI: 0.87, 1.24 and OR = 1.04; 95% CI: 0.88, 1.23, respectively) ([Table 2](#t2){ref-type="table"}). Except for PM~coarse~, estimates were all positive but not significant, though borderline significant for NO~x~ (OR = 1.04; 95% CI: 0.99, 1.08) ([Table 2](#t2){ref-type="table"}).

PM~10~ estimates were positive and tended to increase in any sensitivity analysis, except when excluding EGEA, but never reached significance ([Table 3](#t3){ref-type="table"}). The analyses that were restricted to nonmovers or excluded the 5% extreme value of the pollutants tended to increase the associations (OR = 1.12; 95% CI: 0.91, 1.37 and OR = 1.11; 95% CI: 0.89, 1.37, respectively). In the stratified analyses, slightly stronger associations between PM~10~ and asthma incidence were observed in ever-smokers compared with never-smokers (OR = 1.17; 95% CI: 0.79, 1.74 and OR = 1.01; 95% CI: 0.88, 1.16, respectively) and in women compared with men (OR = 1.07; 95% CI: 0.91, 1.26 and OR = 1.00; 95% CI: 0.63, 1.59, respectively), whereas associations were similar for age \< 50 and ≥ 50 years.

In the bi-pollutant model, the NO~2~ estimate increased from 1.10 (95% CI: 0.99, 1.21) to 1.17 (95% CI: 0.99, 1.38), whereas the PM~10~ estimate decreased from 1.04 (95% CI: 0.88, 1.23) to 0.98 (95% CI: 0.79, 1.21) ([Table 3](#t3){ref-type="table"}).

The comparison of ECRHS results using ESCAPE NO~2~ estimates or the previously published APMoSPHERE NO~2~ estimates ([@r22]) showed that the effect estimates were sensitive to both the analytic approach and the exposure models. Higher effect estimates were observed in the model with study/city used as fixed effect and/or when using the APMoSPHERE exposure model (see Supplemental Material, Table S6). For instance, the estimate based on the ESCAPE model and random effect on city was 1.04 (95% CI: 0.91, 1.20) and increased up to 1.94 (95% CI: 1.27, 2.96) in the model using the APMoSPHERE air pollution exposure and adjusted on city.

Discussion
==========

In this longitudinal investigation, asthma incidence was positively associated with all exposure metrics, except with the coarse fraction of PM. The association was borderline statistically significant for a 10-μg/m^3^ increase in NO~2~ (OR = 1.10; 95% CI: 0.99, 1.21) and significant with back-extrapolated NO~2~ (OR = 1.10; 95% CI: 1.00, 1.20). Overall, these findings provide suggestive but not firm evidence for a role of ambient air pollution on asthma incidence in adults.

The main strengths of this study are a large population from a wide geographical area, including \> 23,000 participants from eight countries and \> 20 different cities across Europe using standardized air pollution estimates at the residential address for a variety of air pollutant metrics. This was achieved through a standardized procedure regarding air pollutants measurements, development of land use regression models, and validation ([@r5]; [@r14]). The lack of highly significant associations in our findings is in line with three interpretations: namely, that there is no such association, that pollutants affect only subgroups of adults, or that we were unable to reliably capture such association as a result of epidemiological bias or lack of power. Overall the validity of those LUR models, assessed with the *R*^2^ (see Supplemental Material, Table S5), were good, although this varied across study sites. We showed that restricting the NO~2~ analyses to the centers with higher *R*^2^ did not modify the results. A simulation study showed that LUR modeling with a small number of measurement sites may bias the health-effect estimates in the form of attenuation toward the null ([@r4]). The lack of association with PM may result partly from the small number of measurement sites for these pollutants. A further limitation was the long lag between the health assessments of most of our cohorts and the standardized ESCAPE measurement campaigns, reaching up to 20 years in some of the cohorts. The resulting exposure misclassification likely contributed to imprecise risk estimates and a bias toward the null ([@r4]). To investigate this, back-extrapolated exposure estimates to the follow-up periods for NO~2~ were analyzed. The odds ratio using back-extrapolated values then reached formal statistical significance, but the effect size, which relied mainly on within-city contrasts, was virtually identical to that in the initial analysis. The validity of back-extrapolation of LUR models is supported by a study showing a good correlation between the 1991 back-extrapolated NO~2~ concentrations estimated from the 2009 LUR model and the NO~2~ concentrations measured by monitoring sites in 1991 ([@r18]). However, back-extrapolated exposure estimates will not account for potential changes over time in spatial contrasts within cities, so their validity may vary by location and time. This is an inherent limitation of the ESCAPE project. Nevertheless, associations with other outcomes investigated in ESCAPE, including mortality ([@r6]) and lung cancer incidence ([@r34]), have been similar for exposures based on ESCAPE measurement period estimates and exposures based on back-extrapolated estimates.

Caution is necessary when interpreting our findings. Although positive, associations with PM and traffic proximity were nonsignificant, which may indicate that these pollutants do not affect adult-onset asthma or that the analyses lacked statistical power to reliably estimate small effects among rather heterogeneous cohorts. The fact that the positive associations with NO~2~ were the closest to statistical significance does not necessarily mean that NO~2~ is the causal pollutant. It could reflect that our exposure model more accurately estimates the true exposure for this pollutant \[which is supported by a trend for a higher *R*^2^ cross-validation of the LUR model for NO~2~ compared with PM~10~ ([@r5]; [@r14])\]. Further, given the correlation between pollutant concentrations, we cannot estimate associations with individual pollutants that account for potential confounding by other pollutants. Moreover, no matter how good the exposure models are, there will always be limitations and potential bias in estimating association using exposure estimates only at home addresses that do not account for the individual spatiotemporal activity.

The design induces some limitation regarding the generalizability of our result to other European cities. For all cohorts, the first inclusion criterion was the availability of ESCAPE models, which varied from 20% for E3N (a national study) to 100% for SALIA and NSHD. At the whole cohort level, follow-up rates were less variable, varying between 60% and 80%, which represents a reasonable follow-up rate for such long-term studies ([@r1]; [@r3]; [@r24]; [@r36]; [@r37]; [@r38]). Though our study is the largest ever conducted in Europe, with the greatest number of countries and areas, and our estimates did not indicate strong heterogeneity in associations across cohorts, some caution is needed in extrapolating our results, particularly in relation to the heterogeneity between areas, and more importantly to the small sample size in each area.

Defining asthma incidence is more challenging than defining outcomes such as mortality ([@r6]) or lung cancer ([@r34]). Furthermore, because adults may not remember early-life wheezing, assessment of adult-onset asthma is difficult ([@r40]). A thorough comparison of questionnaires and protocols was undertaken to harmonize asthma definition across the various cohorts without losing valuable information. Although only ECRHS and SAPALDIA were purposefully designed to assess asthma incidence, we were as rigorous as possible in identifying only incident cases, by excluding participants who reported asthma or, when available, asthma-like symptoms at baseline from our study population. Bias in asthma diagnosis may have been introduced through both different cultural perceptions of asthma in the countries in which the cohorts were located, and the different questionnaires and diagnostic protocols used. In the largest cohort included, E3N, the validity of the simple asthma question used has been investigated in a subsample study, which showed good concordance with questions similar to those used in respiratory surveys and with dispensed asthma drug treatment ([@r36]). Because of a limited number of cohorts with bronchial challenge tests, we were unable to perform a sensitivity analysis defining asthma as new bronchial hyperresponsiveness plus symptoms, as used in a previous study of occupational risk factors for asthma ([@r23]). However, for the three cohorts with information on bronchial hyperresponsiveness, the validity of our incident asthma classification was supported by the increase in bronchial hyperresponsiveness between baseline and follow-up among participants who developed asthma after the baseline examination.

Results should be interpreted in the context of current knowledge and research regarding asthma phenotypes. It is established that childhood-onset asthma, compared with adult-onset asthma, occurs more in males, is more often associated with allergic sensitization, and also depends on specific genetic determinants ([@r8]; [@r46]). With the increase of childhood asthma, the potential recurrence of asthma in adulthood after remission becomes an increasing concern. Recent research on asthma temporal patterns and data-driven phenotyping conducted in four of the six cohorts included in the present analysis show the complexity of asthma variability over periods of around 10 years in adulthood ([@r7]; [@r36]). Asthma in childhood only, adulthood only, old age only, mild (often forgotten) childhood asthma reappearing in adulthood, or persistent asthma throughout the life span are various phenotypes that may depend on both genetic and environmental determinants of various critical windows of expression/exposure. The variability of asthma can be characterized according to different windows of time ([@r15]). These may be short (hours or days), often in relation to triggers of attacks, as well as long (months or years). Lessons from other environmental factors (smoking, occupation) have already shown effects on asthma through acute or subchronic exposures. For example, there is increasing evidence of the role of occupational exposure in the various forms of work-related asthma, which encompasses both occupational asthma starting in adulthood and work-exacerbated asthma ([@r19]). The role of occupational exposure has clearly been evidenced in adult-onset asthma assessed in a birth cohort that was followed until adulthood ([@r16]). The follow-up of the numerous birth cohorts initiated in the 1990s and still followed will likely help us understand the various evolutions of the disease.

Our study considered multiple cohorts across Europe, which increased statistical power. However, this also gave potential for larger population heterogeneity, increasing the potential for confounding and therefore bias in the effect estimates. Particular characteristics of each cohort may have influenced the results, such as the health consciousness and high education of the women in E3N or the greater baseline risk of asthma for members of asthmatic families in EGEA. Indeed, as shown in [Figure 2](#f2){ref-type="fig"}, associations were usually largest in EGEA, reaching statistical significance for NO~2~---although this finding was not robust to the exclusion of the 5% most extreme exposure values (data not shown). To investigate cohort-specific influences on results, we formally tested heterogeneity among cohorts and also looked at the robustness of the findings by removing each cohort in turn, which showed some modest variation.

Overall, nearly all the sensitivity and stratified analyses led to ORs \> 1. Results from stratified analyses should be interpreted with caution because of the limited number of incident cases in subgroups in some cohorts, and none of the *p*-values for interaction were significant (*p* \> 0.35). Surprisingly, the estimates tended to decrease when restricting the analysis to nonmovers for NO~2~ but not for PM~10~. This could be attributable to the lower percentage of movers in E3N and the lack of standardization of moving assessment.

Our results were sensitive to the statistical approach chosen to account for the clustered data, namely using fixed versus random effects for study city/area. Which of the two modeling approaches provides more valid results is difficult to determine, but one factor may be the nature of the air pollutant variation in regards to the within- versus between-city/area. Fixed city/area--effect models estimate purely within-city/area air pollution effects, whereas random-effects models estimate a weighted average of between- and within-city/area effects ([@r31]). The difference between both approaches within our analyses was driven by the ECRHS estimates, possibly explained by the higher between-city/area variation in air pollutant concentration in this European cohort. Further analyses, including simulation studies, are warranted to better address this statistical issue in the context of the air pollution effect estimates.

Compared with other published results for NO~2~, our confidence intervals largely overlapped those from other studies \[OR for 10 μg/m^3^ of NO~2~ = 1.10 (95% CI: 0.99, 1.20) compared with 1.54 (95% CI: 1.00, 2.36) in RHINE ([@r28]) and 1.43 (95% CI: 1.02, 2.01) in ECRHS ([@r22]) and OR for 5.8 ppb of NO~2~ (i.e., 11 μg/m^3^) = 1.12 (95% CI: 0.96, 1.30) in a cohort of U.S. women ([@r47])\]. Interestingly, the association with NO~2~ tended to increase when controlling for PM~10~ concentration. Two of the six cohorts included in our analyses had previously assessed associations between air pollution and asthma incidence in adults. In ECRHS, a positive and significant association was found between individually assigned air pollution exposure derived from a 1 × 1 km air pollution map (APMoSPHERE) and asthma incidence defined in a similar way to ESCAPE ([@r22]) and also in an alternative way based on asthma symptoms ([@r21]). One possible reason for seeing consistently stronger associations with APMoSPHERE based analyses is that APMoSPHERE used air pollution data closer in time to the collection of health data. Alternatively, a spatially less resolved model may better account for the time activity patterns in adult populations; thus, "background" air pollutant exposure estimates could be a better proxy of the mean individual exposure compared with the very local exposure estimates at the home address, produced by the ESCAPE modeling strategy. SAPALDIA ([@r25]) reported significant associations between asthma incidence in never-smokers and individually assigned changes in a specifically modeled marker termed "traffic related PM~10~." ESCAPE had no such marker, so direct comparisons cannot be made. Moreover, only three SAPALDIA areas were included in ESCAPE---and only one with PM---whereas all previous SAPALDIA results were based on the eight areas the cohort had been designed for in 1990.

Various mechanisms have been proposed to explain the associations of air pollution with asthma. Active ongoing research is being conducted to disentangle the various asthma phenotypes and assess which mechanisms may be specifically involved. Because childhood-onset asthma is more often associated with allergic sensitization, it could be hypothesized that allergy-related mechanisms influence childhood asthma relapsing in adulthood. However, recent results from ESCAPE in children up to 10 years of age did not show evidence of associations of air pollution exposure with allergic sensitization ([@r17]). This suggests that nonallergic mechanisms, for which interest is increasing for asthma at any age, are particularly important to consider. Increased frailty of the epithelial barrier, inflammation, oxidative stress, and interaction with genetic and epigenetic determinants have been proposed. Research in adults, including subjects from the cohorts included in our analysis, has suggested a role of air pollution in local inflammation measured in exhaled breath condensate and induced sputum (using ESCAPE exposure estimates) ([@r44]), interaction with oxidative stress genes ([@r10]), or novel DNA methylation markers ([@r39]). Ambitious programs with comprehensive environmental exposure assessment and biological markers are starting in childhood populations ([@r45]). Altogether, adult-onset asthma is only one of the various asthma phenotypes, and comprehensive life course approaches should be developed at the environmental and phenotypic levels.

Conclusion
==========

With \> 23,000 adults across Europe followed for 10 years, including 1,257 incident cases of asthma, this is the largest study to estimate the association between traffic-related air pollution, assessed using a standardized and validated method at the individual level, and asthma incidence in adults. Our findings provide suggestive but no firm evidence for a role of air pollution exposure on asthma incidence in adults. Further research with improved individual-level exposure assessment (taking into account, for example, time--activity patterns) and phenotypic characterization in a life-course perspective is needed to better understand the effect of air pollutants on asthma.
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=====================
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